Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 11:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 7,224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control of Symptoms Clear all
Completed Phase 2 Interventional

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

NCT05536414
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Centanafadine, Escitalopram, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
62
States / cities
Yuma, Arizona • Bryant, Arkansas • Glendale, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

NCT05223478
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Longwood, Florida • Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 30, 2026, 11:43 AM EDT
Active, not recruiting Phase 3 Interventional

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

NCT03040778
View directory record Official record
Conditions
Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis
Interventions
Pentoxifylline, Placebo, Tocopherol
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Ann Arbor, Michigan • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 30, 2026, 11:43 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of CRD-4730 in CPVT

NCT06658899
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
CRD-4730, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
San Francisco, California • Morrisville, North Carolina • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

NCT05669599
View directory record Official record
Conditions
Obesity, Overweight, Type 2 Diabetes Mellitus
Interventions
Maridebart Cafraglutide, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AB103 Peptide Antagonist in Healthy Volunteers

NCT01166984
View directory record Official record
Conditions
Healthy Volunteer Safety Study
Interventions
AB103, Placebo
Drug
Lead sponsor
Atox Bio Ltd
Industry
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Mental Health First Aid for College Students

NCT02021344
View directory record Official record
Conditions
Depression, Anxiety, Suicidal Ideation, Eating Disorders
Interventions
Mental Health First Aid
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
2,543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 27, 2013 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Reducing Eating Disorder Risk Factors Among College-Aged Males

NCT03013244
View directory record Official record
Conditions
Eating Disorder
Interventions
The Body Project: More Than Muscles
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

NCT00110487
View directory record Official record
Conditions
Endometriosis
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Carmichael, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

NCT01818921
View directory record Official record
Conditions
Obesity, Over-weight, Prader-Willi Syndrome
Interventions
ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
Drug
Lead sponsor
Zafgen, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

NCT05034952
View directory record Official record
Conditions
Acute Pain
Interventions
VX-548, HB/APAP, Placebo (matched to VX-548), Placebo (matched to HB/APAP)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
7
States / cities
Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 3 Interventional

Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)

NCT00086658
View directory record Official record
Conditions
Hypereosinophilia, Hypereosinophilic Syndrome
Interventions
mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
San Diego, California • Denver, Colorado • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 30, 2026, 11:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices

NCT06168058
View directory record Official record
Conditions
Chronic Pelvic Pain Syndrome, Pelvic Pain, Pelvic Varices, Pelvic Congestive Syndrome, Pelvic Pain Syndrome
Interventions
Transcatheter Venography, Bilateral ovarian vein embolization
Diagnostic Test · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
New Hyde Park, New York • New York, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

NCT05325775
View directory record Official record
Conditions
Post-menopausal Vasomotor Symptoms
Interventions
ACER-801 50 mg BID, ACER-801 100 mg BID, ACER-801 200 mg BID, Placebo
Drug
Lead sponsor
Acer Therapeutics Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Sep 30, 2026, 11:43 AM EDT
Recruiting Phase 3 Interventional

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06911112
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NBI-1065845, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Huntsville, Alabama • Bryant, Arkansas • Glendale, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 30, 2026, 11:43 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

NCT01416181
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Results available

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

NCT05307692
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
55 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Tempe, Arizona • Lafayette, California • Homestead, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males

NCT00493311
View directory record Official record
Conditions
Fever
Interventions
IV Placebo, IV Acetaminophen, Reference Standard Endotoxin (RSE)
Drug · Biological
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Sep 30, 2026, 11:43 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Personalized HIV and STI Testing Tool

NCT03109899
View directory record Official record
Conditions
Risk Reduction, HIV, Sexually Transmitted Infections (Not HIV or Hepatitis)
Interventions
Sex Pro mobile Application
Behavioral
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Meru Health Program Versus Waitlist Control for Adults With Depression

NCT04738084
View directory record Official record
Conditions
Depression
Interventions
Meru Health Program
Behavioral
Lead sponsor
Meru Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 30, 2026, 11:43 AM EDT
Recruiting Phase 2 Interventional

A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

NCT07570758
View directory record Official record
Conditions
Obesity & Overweight
Interventions
ERX1000, Placebo
Drug · Other
Lead sponsor
ERX Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Louisville, Kentucky • Monroe, North Carolina • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Results available

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

NCT00507455
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions
solifenacin succinate, tamsulosin hydrochloride, Placebo to solifenacin, Placebo to tamsulosin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Homewood, Alabama • La Mesa, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Sep 30, 2026, 11:43 AM EDT
Not listed Not applicable Interventional

Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)

NCT01213914
View directory record Official record
Conditions
Burns, Hemofiltration, Kidney Failure, Acute, Shock, Septic
Interventions
An FDA approved continuous renal replacement device, Control Group
Device · Other
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Sep 30, 2026, 11:43 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effect of Mindfulness Training on Sleep and Inflammation Among Older Adults With Sleep Problems

NCT01534338
View directory record Official record
Conditions
Sleep Problems, Inflammation
Interventions
Mindfulness Meditation, Sleep Education
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Sep 30, 2026, 11:43 AM EDT